Assessment
durvalumab
Resectable muscle-invasive bladder carcinoma (MIBC) eligible for platinum-based chemotherapy; neoadjuvant treatment in combination with gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations